These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 32806956)

  • 1. Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look.
    Ricci AD; Rizzo A; Brandi G
    Cancer Control; 2020; 27(3):1073274820948047. PubMed ID: 32806956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances of immunotherapy for biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):527-536. PubMed ID: 33215952
    [No Abstract]   [Full Text] [Related]  

  • 3. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
    [No Abstract]   [Full Text] [Related]  

  • 4. Nivolumab: an investigational agent for the treatment of biliary tract cancer.
    Di Federico A; Rizzo A; Ricci AD; Frega G; Palloni A; Tavolari S; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):325-332. PubMed ID: 33307866
    [No Abstract]   [Full Text] [Related]  

  • 5. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
    Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
    Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
    Rizzo A; Ricci AD; Brandi G
    Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer.
    Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y;
    Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma).
    Jakubowski CD; Azad NS
    Chin Clin Oncol; 2020 Feb; 9(1):2. PubMed ID: 32008328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging immunotherapeutic approaches for biliary tract cancers.
    Yuan ZG; Zeng TM; Tao CJ
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):440-449. PubMed ID: 36115807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunotherapy for biliary tract cancers.
    Zhao Y; Yang M; Feng J; Wang X; Liu Y
    Chin Med J (Engl); 2024 Mar; 137(5):524-532. PubMed ID: 37646139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of up-and-coming immune checkpoint inhibitors for pancreatic cancer.
    Mahadevia H; Uson Junior PLS; Wang J; Borad M; Babiker H
    Expert Opin Pharmacother; 2024; 25(1):79-90. PubMed ID: 38193476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience?
    Brandi G; Rizzo A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Clinical Trial Results of the Recently Approved Immunotherapeutic Drugs for Advanced Biliary Tract Cancers.
    Das S
    Rev Recent Clin Trials; 2024; 19(2):81-90. PubMed ID: 38288802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and patients treated for cancer with microsatellite instability.
    Colle R; Cohen R; Cochereau D; Duval A; Lascols O; Lopez-Trabada D; Afchain P; Trouilloud I; Parc Y; Lefevre JH; Fléjou JF; Svrcek M; André T
    Bull Cancer; 2017 Jan; 104(1):42-51. PubMed ID: 27979364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
    Goeppert B; Roessler S; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil A; Czink E; Köhler B; Springfeld C; Pfeiffenberger J; Rupp C; Weiss KH; Schirmacher P; von Knebel Doeberitz M; Kloor M
    Br J Cancer; 2019 Jan; 120(1):109-114. PubMed ID: 30377340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer.
    Yue S; Zhang Y; Zhang W
    Curr Treat Options Oncol; 2024 Aug; 25(8):1089-1111. PubMed ID: 39066855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1-dependent immune response in colorectal cancer.
    Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
    J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA Checkpoint Gene Mutation as a Biomarker for Immune Checkpoint Inhibitor Therapy in Advanced Biliary Tract Cancer.
    Shin JE; Kim ST
    Anticancer Res; 2024 May; 44(5):2103-2108. PubMed ID: 38677768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes.
    Chen X; Wang D; Liu J; Qiu J; Zhou J; Ying J; Shi Y; Wang Z; Lou H; Cui J; Zhang J; Liu Y; Zhao F; Pan L; Zhao J; Zhu D; Chen S; Li X; Li X; Zhu L; Shao Y; Shu Y
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers.
    Giorgione R; Risaliti M; Bartolini I; Rossi G; Pillozzi S; Muiesan P; Taddei A; Antonuzzo L
    Immunotherapy; 2022 May; 14(7):567-576. PubMed ID: 35382560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.